---
title: "Turn Therapeutics expands GX-03 Phase 2 atopic dermatitis study after interim analysis shows broader efficacy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291930038.md"
description: "Turn Therapeutics has expanded the enrollment criteria for its Phase 2 trial of topical GX-03 in atopic dermatitis following an interim analysis showing broader efficacy. The study will now include patients with baseline EASI scores as low as 1.1, targeting 120-135 participants stratified by severity. Week 4 endpoints are added to Week 8 measures, with enrollment expected to conclude in Q4 2026 and funding runway through Q3 2027."
datetime: "2026-07-07T12:07:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291930038.md)
  - [en](https://longbridge.com/en/news/291930038.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291930038.md)
generator: "portal-rs"
---

# Turn Therapeutics expands GX-03 Phase 2 atopic dermatitis study after interim analysis shows broader efficacy

-   Turn Therapeutics set the final Stage 2 design for its adaptive Phase 2 trial of topical GX-03 in atopic dermatitis. \* Interim analysis supported expanding enrollment to cover the full baseline EASI severity spectrum, starting at EASI ≥1.1. \* Stage 2 targets 120-135 patients, stratified by baseline EASI, with 1:1 randomization within each stratum. \* Week 4 showed the clearest treatment separation; Stage 2 adds Week 4 endpoints alongside Week 8 measures. \* Enrollment expected to finish in the fourth quarter of 2026; runway projected through the third quarter of 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260707654155) on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TTRX.US](https://longbridge.com/en/quote/TTRX.US.md)

## Related News & Research

- [Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%](https://longbridge.com/en/news/296487429.md)
- [Turn Therapeutics sells 135,000 shares in private placement for $1.35 million](https://longbridge.com/en/news/296141997.md)
- [Nykode Therapeutics announces availability of Q2 2026 financial results report](https://longbridge.com/en/news/297025454.md)
- [BHP advances natural capital valuation with first operated-asset baseline and accounting approach](https://longbridge.com/en/news/296159125.md)
- [Doubleview Appoints Edward Huebert as Vice President, Permitting, Regulatory & Indigenous Relations | DBLVF Stock News](https://longbridge.com/en/news/297016582.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**